DelveInsight’s ‘Molluscum Contagiosum Pipeline Insight 2023‘ report provides comprehensive global coverage of pipeline Molluscum Contagiosum therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Molluscum Contagiosum pipeline domain.
For Molluscum Contagiosum emerging drugs, the Molluscum Contagiosum pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Key Takeaways from the Molluscum Contagiosum Pipeline Report
- DelveInsight’s Molluscum Contagiosum Pipeline analysis depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Molluscum Contagiosum treatment.
- The leading Molluscum Contagiosum companies include Novan, Veloce Biopharma, Verrica Pharmaceuticals, Santalis Healthcare, and others are evaluating their lead assets to improve the Molluscum Contagiosum treatment landscape.
- Key Molluscum Contagiosum pipeline therapies in various stages of development include SB-206 (Berdazimer Sodium), VBP-245 (Povidone Iodine Topical), Santalum album cream, and others.
- In July 2023, the FDA approved Ycanth (cantharidin) as an in-office administered drug for the topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older.
- In March 2023, the FDA approved a new drug application for Novan’s berdazimer gel to treat molluscum contagiosum.
Request a sample and discover the recent breakthroughs happening in the Molluscum Contagiosum pipeline landscape @ Molluscum Contagiosum Pipeline Outlook
Molluscum Contagiosum Overview
Molluscum Contagiosum is a common viral skin infection that causes pinkish, firm, spherical, and painless lumps on the skin. The size of the hump might range from a few millimeters to 2-5 millimeters in diameter. The poxvirus Molluscum contagiosum causes the sickness. When touched, the lesion becomes red, swollen, and itchy, and it can spread to other parts of the body. Physical contact or contaminated fomites can spread the disease from person to person. Although molluscum contagiosum is prevalent, people with compromised immune systems, atopic dermatitis, or who live in warm, damp, and crowded environments are more susceptible to infection. The infection is not age-specific, but it is most frequent in children between one to ten years.
Find out more about Molluscum Contagiosum medication @ New Drug for Molluscum Contagiosum
Molluscum Contagiosum Treatment Analysis: Drug Profile
SB 206 (Berdazimer Sodium): Novan Inc
SB 206, Novans’ novel therapeutic candidate, is a topically applied drug molecule in development for the treatment of molluscum contagiosum. SB 206 has been shown in phase I and II studies to be effective in the treatment of molluscum contagiosum. The medicine works by acting as a nitric oxide donor to eliminate the virus.
VBP-245 (Povidone Iodine Topical): Veloce Biopharma
VBP-245, a drug developed by Veloce, is now being studied for the treatment of Molluscum Contagiosum and has exhibited a favorable safety and effectiveness profile in phase I trials. VBP-245 is an antiviral medication that blocks the HN protein, which is crucial for virus attachment to host cells.
Key Molluscum Contagiosum Therapies and Companies
- SB 206 (Berdazimer Sodium): Novan Inc
- VBP-245 (Povidone Iodine Topical): Veloce Biopharma
- VP-102 (Cantharidin): Verrica Pharmaceuticals
- Santalum album cream: Santalis Healthcare
Learn more about the novel and emerging Molluscum Contagiosum pipeline therapies @ Molluscum Contagiosum Clinical Trials
Molluscum Contagiosum Therapeutics Assessment
- By Product Type
- Monotherapy
- Combination Therapy
- By Stage
- Discovery
- Pre-Clinical
- Phase I
- Phase II
- Phase III
- Pre-registration
- By Route of Administration
- Oral
- Subcutaneous
- Intravenous
- Intramuscular
- By Molecule Type
- Monoclonal Antibody
- Peptides
- Small molecule
Scope of the Molluscum Contagiosum Pipeline Report
- Coverage: Global
- Key Molluscum Contagiosum Companies: Novan, Veloce Biopharma, Verrica Pharmaceuticals, Santalis Healthcare, and others.
- Key Molluscum Contagiosum Pipeline Therapies: SB-206 (Berdazimer Sodium), VBP-245 (Povidone Iodine Topical), Santalum album cream, and others.
Dive deep into rich insights for drugs used for Molluscum Contagiosum treatment; visit @ Molluscum Contagiosum Drugs
Table of Contents
| 1. | Introduction |
| 2. | Executive Summary |
| 3. | Molluscum Contagiosum Pipeline: Overview |
| 4. | Analytical Perspective In-depth Commercial Assessment |
| 5. | Molluscum Contagiosum Pipeline Therapeutics |
| 6. | Molluscum Contagiosum Pipeline: Late Stage Products (Phase III) |
| 7. | Molluscum Contagiosum Pipeline: Late Stage Products (Phase III) |
| 8. | Molluscum Contagiosum Pipeline: Mid-Stage Products (Phase II) |
| 9. | Molluscum Contagiosum Pipeline: Early Stage Products (Phase I) |
| 10. | Therapeutic Assessment |
| 11. | Inactive Products |
| 12. | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13. | Key Companies |
| 14. | Key Products |
| 15. | Unmet Needs |
| 16. | Market Drivers and Barriers |
| 17. | Future Perspectives and Conclusion |
| 18. | Analyst Views |
| 19. | Appendix |
For further information on the Molluscum Contagiosum therapy in the pipeline, reach out @ Molluscum Contagiosum Medication
Related Reports
Common Warts Pipeline Insight, 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Common Warts companies involved such as Nielsen BioSciences, Veloce BioPharma, Verrica Pharmaceutical, among others.
Common Warts Epidemiology Forecast
Common Warts Epidemiology Forecast to 2032 report delivers an in-depth understanding of the disease, historical, and forecasted Common Warts epidemiology in the 7MM.
Warts Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Warts companies such as Maruho, Aclaris Therapeutics, among others.
Genital Warts Market Insights, Epidemiology, and Market Forecast-2030 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Genital Warts companies such as Verrica Pharmaceuticals, Novan Inc., G&E Herbal Biotechnology, among others.
Genital Warts Pipeline Insight, 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Genital Warts companies involved such as ViroXis Corporation, bioRASI, LLC, Verrica Pharmaceuticals Inc., Orgenesis, among others.
Warts Pipeline Insight, 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Warts companies involved such as Cytovation, Novan, Verrica Pharmaceuticals, among others.
Other Trending Reports
Anemia Market | Blood Glucose Monitoring Systems Market | Chronic Myelogenous Leukemia Market | Allergic Rhinitis Market | Acute Pulmonary Embolism Market | Autonomic Dysfunction Market | Chronic Progressive Multiple Sclerosis Market | Progressive Familial Intrahepatic Cholestasis Market | Artificial Lung Devices Market | Complicated Intra-abdominal Infections Market | Ophthalmic Imaging Equipment Market | Ctcl Market | Interbody Cages Market | Ambulatory Arrhythmia Monitoring Devices Market | Chronic Rhinosinusitis Market | Postmenopausal Vaginal Atrophy Market | Refractory Angina Market | Acute Agitation And Aggression Market | Giant Papillary Conjunctivitis Market | Carcinoid Tumor Market | Urolithiasis Market | Alopecia Areata Market | Airway Stent Market Market | Cluster Headache Market | Subscription Healthcare | Cancer Anorexia Market | Hereditary Spastic Paraplegias Market | Post-transplant Lymphoproliferative Disease Market | Bladder Pain Syndrome Market | Cutaneous Lupus Erythematosus Market | Nonmuscle Invasive Bladder Cancer Market | Palmar Hyperhidrosis Market Size | Thrombocytopenia Market | Acrocallosal Syndrome Market | Acute Radiation Syndrome Market | Benefits Of Robotics In Healthcare | Burkitt Lymphoma Market | Idiopathic Pulmonary Fibrosis Market | Osteosarcoma Market | Arthroscopy Devices Market | Bronchial Spasm Market | Familial Amyloid Polyneuropathy Market | Radiation Toxicity Market | Spasticity Market | Acute Coronary Syndrome Market | Bunion Market
Related Healthcare Services
- Healthcare Consulting
- Healthcare Competitive Intelligence Services
- Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect With Us at LinkedIn | Facebook | Twitter
Contact Us
Sandeep Joshi
info@delveinsight.com
+1(919)321-6187